Browse the evidence

High-fat diets (HFD) induce insulin resistance in rodents primarily through the accumulation of diacylglycerol (DAG) and ceramides, which inhibit insulin signaling via PKC and PP2A activation respectively.

This explains why high-fat diets can lead to metabolic issues at a cellular level: excess fat storage in organs like the liver and muscle triggers specific molecules (DAG and ceramides) that block insulin's ability to signal for glucose uptake.

Bariatric surgery does NOT significantly reduce the incidence of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma compared to conventional treatment.

While bariatric surgery reduces many obesity-related cancers, it does not appear to significantly lower the risk of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma.

Racial and ethnic minorities, particularly Black and American Indian/Alaskan Native individuals, have significantly lower initiation rates of newer diabetes medications (GLP-1RAs, DPP-4Is, SGLT-2Is) compared to White individuals, independent of socioeconomic factors.

If you are a minority patient with type 2 diabetes, you may face systemic barriers to accessing newer, highly effective medications like GLP-1s or SGLT-2 inhibitors, even if you have insurance. These drugs offer significant cardiovascular and kidney benefits. It is crucial to discuss these options with your provider, understand your insurance formulary, and advocate for yourself, as disparities in initiation are well-documented and often driven by systemic factors rather than medical necessity.

Brainstem cholecystokinin-expressing (CCKAP/NTS) neurons are necessary for GLP-1 receptor agonists to induce conditioned taste avoidance (nausea/aversive effects).

The nausea and aversion caused by GLP-1 medications are mediated by specific brainstem neurons (CCKAP/NTS). Blocking these neurons prevents the aversive response, confirming that nausea is a central brain effect, not just a stomach issue. This knowledge helps in managing expectations and potentially developing strategies to reduce nausea.

Circulating levels of trans-16:1n9 and total trans-18:1 are not significantly associated with total mortality or cardiovascular disease mortality in older adults.

You do not need to avoid natural sources of trans fats (like those found in dairy and meat) which contain t-16:1n9 and t-18:1, as this study found no link to increased mortality or heart disease risk. Focus your efforts on avoiding industrial trans fats (partially hydrogenated oils) instead.

Genetic disruption of AMPK-glycogen binding in skeletal muscle (via AMPK beta2 subunit mutation) leads to increased adiposity and impaired glucose handling, whereas disruption in liver (via AMPK beta1 subunit mutation) primarily increases hepatic fat deposition without affecting whole-body glucose handling.

This research highlights that the body's energy sensors (AMPK) rely on glycogen stores for stability. Disrupting this link impairs metabolic health. While this is a genetic model, it suggests that maintaining healthy glycogen stores through balanced carbohydrate intake and regular physical activity is crucial for optimal metabolic function and preventing ectopic fat accumulation.

Adherence to dipeptidyl peptidase-4 (DPP4) inhibitor therapy has no significant association with weight change in patients with type 2 diabetes.

If you are prescribed a DPP4 inhibitor for type 2 diabetes, note that adherence does not significantly affect your weight. These medications are weight-neutral, so focus on other aspects of your treatment plan for weight management.

Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.

If you have severe, early-onset obesity and insatiable hunger (hyperphagia) that persists despite strict dieting or surgery, standard approaches may not work because of a genetic disruption in your brain's hunger signals. You should seek genetic testing and specialized care to access targeted therapies (like setmelanotide) that address the root hormonal cause rather than just calories.

Engineered E. coli Nissle strains (SYNB1618 and SYNB1934) expressing phenylalanine-degrading enzymes successfully reduce fasting plasma phenylalanine levels in patients with Phenylketonuria (PKU) in Phase 1/2a and Phase 2 trials.

For PKU patients, engineered bacteria are showing promise in clinical trials to lower blood phenylalanine levels. This could eventually offer more dietary flexibility, but these treatments are not yet widely available.

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Higher genetically predicted BMI does not increase the risk of cancer mortality.

While higher BMI increases risks for other causes of death, this study did not find a link to cancer mortality.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

Serum resistin concentrations are not significantly correlated with insulin sensitivity (glucose disposal rate) in obese or obese diabetic humans, indicating resistin is unlikely to be a major mediator of insulin resistance in these populations.

For individuals with obesity or type 2 diabetes, serum resistin levels are not a reliable indicator of insulin sensitivity, nor is lowering resistin likely to be a primary strategy for improving insulin resistance. Focus on established interventions like weight management and physical activity rather than targeting resistin specifically.

Serum resistin levels are directly correlated with resistin mRNA expression in abdominal subcutaneous adipose tissue, suggesting adipose tissue is a source of circulating resistin.

Measuring resistin mRNA in fat biopsies is a valid proxy for estimating serum resistin levels in obese individuals, as they are strongly correlated.

Tele-based health coaching for patients with Type 2 Diabetes (T2D) or Coronary Artery Disease (CAD) does not produce a statistically significant reduction in total healthcare and long-term care costs over an 8-year follow-up period compared to usual care.

For healthcare administrators and policymakers, this study indicates that tele-based health coaching for T2D and CAD patients should not be implemented primarily as a cost-saving measure over an 8-year horizon, as it does not significantly reduce total healthcare and long-term care costs compared to usual care. Decision-makers should focus on clinical outcomes and patient empowerment rather than expected financial savings when evaluating this intervention.

A 12-week theory-based diabetes self-management education program (BGI) provides no significant long-term benefit for cardiovascular risk factors, self-management behaviors, or quality of life in patients with Type 2 diabetes who already have well-controlled biomedical markers.

If you already have well-controlled Type 2 diabetes (normal HbA1c, blood pressure, and cholesterol), a standard 12-week self-management education program is unlikely to further improve your health numbers or quality of life compared to your regular doctor visits. Focus on maintaining your current successful routine rather than seeking additional structured education programs.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

In people with suppressed HIV and metabolic dysfunction-associated fatty liver disease (MAFLD), adjunctive treatment with maraviroc, metformin, or their combination for 48 weeks does not significantly reduce liver fat fraction compared to antiretroviral therapy alone.

If you have HIV and fatty liver, adding maraviroc or metformin to your standard HIV treatment is unlikely to reduce the fat in your liver. The trial showed no significant benefit for liver fat reduction compared to just staying on your HIV medication. Focus on proven lifestyle strategies for metabolic health.

Childhood adversities are associated with an increased risk of fatal or non-fatal CHD events in adulthood.

Early life trauma has long-lasting physical consequences, increasing the risk of heart disease later in life. While you cannot change your childhood, being aware of this risk factor allows for more proactive cardiovascular monitoring and stress management in adulthood.

Combined therapy with interferon-alfa and ribavirin for 48 weeks is effective and cost-effective for treating mild chronic hepatitis C in patients under 65, achieving sustained virological response (SVR) rates of 33% overall and 49% for non-genotype 1.

For adults with mild chronic hepatitis C, a 48-week course of interferon-alfa and ribavirin is a clinically effective and economically viable option, particularly for those under 65 and those with non-genotype 1 strains. While the treatment causes temporary side effects and a dip in quality of life, successful clearance of the virus (SVR) leads to long-term health benefits and improved quality of life, making it a superior choice to 'watchful waiting' for this demographic.

Antiviral treatment for mild chronic hepatitis C is not cost-effective for patients aged 65 or over with genotype 1, as it leads to fewer QALYs gained.

For patients aged 65 or older with genotype 1 mild hepatitis C, antiviral treatment is generally not recommended as cost-effective because it may not improve quality-adjusted life years and costs significantly more than the threshold for value. In these cases, regular monitoring (liver biopsy) is likely the more prudent clinical strategy.

PPARgamma agonists (thiazolidinediones like rosiglitazone) improve insulin sensitivity in obese models by downregulating macrophage-derived inflammatory gene expression in white adipose tissue.

Drugs that activate PPARgamma (like rosiglitazone) work partly by calming inflammation in fat tissue. This suggests that anti-inflammatory strategies might be a valid adjunct to metabolic health management in obesity.